Biomedical Applications of Topical Formulations for Skin and Mucosal Disorders

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 15 April 2024 | Viewed by 1224

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, University Campus of Cartuja, 18071 Granada, Spain
Interests: topical dosage forms; drug delivery; transdermal and transmucosal route; micro- and nanoencapsulation; tissue engineering; cosmetics and dermopharmacy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
Interests: topical drug delivery systems; dermal absorption; skin models; in vitro studies; nanomedicine; transdermal delivery; transmucosal delivery; cronocosmetic
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
Interests: nanocarriers; topical drug delivery systems; dermal absorption; skin models; in vitro studies; nanomedicine; transdermal delivery; transmucosal delivery; cronocosmetic; skin biodistribution
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin and mucosal disorders are conditions that affect the skin and mucous membranes, which are linings in various parts of the body, including the mouth, nose, throat, and genitals. Some common skin and mucosal disorders include eczema, atopic dermatitis, psoriasis, acne, rosacea, cold sores, oral mucositis, vaginal infections, etc. These disorders can have a significant impact on a person's quality of life, causing discomfort, pain, and embarrassment.

Effective management of these conditions often involves the use of topical formulations, which play a vital role in the management of various skin and mucosal disorders, providing targeted and effective treatment options for patients.

This Special Issue focuses on recent studies that aim to develop and evaluate topical formulations as well as their biomedical applications. Both research and review articles are welcome.

Dr. Beatriz Clares
Prof. Dr. Ana C. Calpena
Dr. Mireia Mallandrich Miret
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin disorders
  • mucosal disorders
  • topical diseases
  • topical formulations
  • transdermal drug delivery
  • transmucosal drug delivery
  • nanocarriers
  • liposomes
  • lipid-based nanostructured systems
  • nanoparticles
  • gels
  • hydrogels
  • smart polymeric systems

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3245 KiB  
Article
Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches
by Sangseo Kim, Souha H. Youssef, Kyung Min Kirsten Lee, Yunmei Song, Sachin Vaidya and Sanjay Garg
Pharmaceutics 2024, 16(3), 379; https://doi.org/10.3390/pharmaceutics16030379 - 10 Mar 2024
Viewed by 869
Abstract
5-fluorouracil (5-FU), commercially available as a topical product, is approved for non-melanoma skin cancer (NMSC) treatment with several clinical limitations. This work aimed to develop 5-FU-loaded topical patches as a potential alternative to overcome such drawbacks. The patches offer accurate dosing, controlled drug [...] Read more.
5-fluorouracil (5-FU), commercially available as a topical product, is approved for non-melanoma skin cancer (NMSC) treatment with several clinical limitations. This work aimed to develop 5-FU-loaded topical patches as a potential alternative to overcome such drawbacks. The patches offer accurate dosing, controlled drug release and improved patient compliance. Our study highlights the development of Eudragit® E (EuE)-based drug-in-adhesive (DIA) patches containing a clinically significant high level of 5-FU (approximately 450 µg/cm2) formulated with various chemical permeation enhancers. The patches containing Transcutol® (Patch-TRAN) or oleic acid (Patch-OA) demonstrated significantly higher skin penetration ex vivo than their control counterpart, reaching 5-FU concentrations of 76.39 ± 27.7 µg/cm2 and 82.56 ± 8.2 µg/cm2, respectively. Furthermore, the findings from in vitro permeation studies also validated the superior skin permeation of 5-FU achieved by Patch-OA and Patch-TRAN over 72 h. Moreover, the EuE-based DIA patch platform demonstrated suitable adhesive and mechanical properties with an excellent safety profile evaluated through an inaugural in vivo human study involving 11 healthy volunteers. In conclusion, the DIA patches could be a novel alternative option for NMSC as the patches effectively deliver 5-FU into the dermis layer and receptor compartment ex vivo for an extended period with excellent mechanical and safety profiles. Full article
Show Figures

Graphical abstract

Back to TopTop